Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019) Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al. Conference contribution Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019) Marme F, Solbach C, Michel L, Fasching P, Schneeweiss A, Blohmer JU, Rezai M, et al. Conference contribution Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer (2019) Fasching P, Huang M, Cortes J, Zhao J, O'Shaughnessy J, Hu P, Haiderali A, et al. Conference contribution Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC) (2019) Eckstein M, Hartmann A, Strissel P, Strick R, Wach S, Taubert H, Wullich B, et al. Conference contribution Salivary and hair cortisol as biomarkers of emotional and behavioral symptoms in 6–9 year old children (2019) Golub Y, Kuitunen-Paul S, Panaseth K, Stonawski V, Frey S, Steigleder R, Grimm J, et al. Journal article Erratum: Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature communications (2019) 10 1 (431)) (2019) Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, et al. Journal article, Erratum Nab-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto (2019) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Journal article Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study (2019) Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, et al. Journal article A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study (2019) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis (2019) Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, Walther A, et al. Journal article